Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00315497 · ClinicalTrials.gov registry record
Determining Disease Activity Biomarkers in Individuals With Giant Cell Arteritis
A clinical trial, sponsored by University of Pennsylvania.
- Completed
- Registry status
- 426
- Enrollment target
NCT00315497: Completed study, sponsored by University of Pennsylvania.
NCT00315497 is a clinical trial that has completed, run by University of Pennsylvania. The registered enrollment target is 426 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00315497 has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- 426 participants
- Enrollment target
Study Summary
Giant cell arteritis (GCA), also known as temporal arteritis, is a disease that usually only occurs in older adults. GCA causes inflammation of blood vessels, or vasculitis. In order to properly treat this disease, it is critical that the level of disease activity can be determined over the course of the disease. The purpose of this study is to determine new biological markers, or biomarkers, that may be used to assess the severity of disease in people with GCA.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 426 participants |
| Start Date | 2006-04 |
| Est. Completion | 2019-12 |
What the finished NCT00315497 record still lists
NCT00315497 is an observational study that tracks outcomes without assigning an intervention. The registered 426 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00315497 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00315497 about?
NCT00315497 is a clinical study titled "Determining Disease Activity Biomarkers in Individuals With Giant Cell Arteritis". Giant cell arteritis (GCA), also known as temporal arteritis, is a disease that usually only occurs in older adults. GCA causes inflammation of blood vessels, or vasculitis. In order to properly treat this disease, it is critical that the level of disease activity can be determined over the course o...
What is the current status of trial NCT00315497?
This trial is currently completed. The enrollment target is 426 participants. The study started on 2006-04. Estimated completion is 2019-12.
Who is sponsoring clinical trial NCT00315497?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06790784 · 426 participants · Phase 3
Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR
- NCT04265430 · 425 participants · Phase 4
Serial Magnetic Resonance Imaging for the Prediction of Radiation-Induced Changes in Normal Tissue of Patients With Oral Cavity or Skull Base Tumors
- NCT04278690 · 425 participants · NA
Supporting Safe Use of Medications by Parents After Infant Discharge From the Neonatal Intensive Care Unit
- NCT05321368 · 425 participants · NA
A Cardiometabolic Health Program Linked With Clinical-Community Support and Mobile Health Telemonitoring to Reduce Health Disparities
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia